Advanced prostate cancer refers to prostate cancer that has spread beyond the prostate, either to nearby tissues/lymph nodes or distant organs such as bone. Management usually requires systemic therapy and multidisciplinary care.
A post hoc STAMPEDE analysis found lower on-treatment PSA levels were strongly associated with improved long-term survival in advanced prostate cancer, but disease burden still affected outcomes.
The radioligand therapeutics market in cancer treatment is estimated to grow from $2.6 billion in 2025 to $4.8 billion by 2030 at a 13.1% CAGR. Growth is supported by approved products Pluvicto and Lutathera and expanding use of PSMA and SSTR-targeted therapies.
An experimental immunotherapy drug shows tumor shrinkage in prostate cancer patients, while Eli Lilly's selpercatinib reduces recurrence risk in early-stage lung cancer. A separate study reveals persistent racial disparities in curative treatment for lung cancer patients.
New research shows genomic profiling can detect aggressive prostate cancer not identified at biopsy, while a separate study reveals PTGES3 as a potential therapeutic target for treatment-resistant disease.
Medicus Pharma reported Phase 2 SKNJCT-003 topline data showing 73% clinical clearance and 40% histological clearance at Day 57 in the 200μg cohort. Separately, the FDA cleared the company to begin a Phase 2b dose optimization study for Teverelix in advanced prostate cancer.
A T-cell engager drug called VIR-5500 demonstrated tumor shrinkage or growth halt in 45% of evaluable patients with advanced prostate cancer in a phase 1 trial, with 88% experiencing only mild side-effects.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07567846 |
A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07457164 |
A Study Investigating the Pharmacokinetics, Pharmacodynamics, Efficacy and Safety of Teverelix DP, a Gonadotropin-releasing Hormone (GnRH) Antagonist, in Patients With Advanced Prostate Cancer |
NOT_YET_RECRUITING | PHASE2 |
| NCT07198633 |
A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07115446 |
Phase Ib Study of HS-20093+HRS-5041 in Patients With Advanced Prostate Cancer |
RECRUITING | PHASE1 |
| NCT07004582 |
Lab Research Using Mini-tumors to Study Prostate Cancer Treatments |
RECRUITING | |
| NCT06984159 |
The Study Will Evaluate if Leuprolide Mesylate is Safe and Effective in the Treatment of Subjects With Advanced Prostate Carcinoma, When Administered as Two Injections Six Months Apart. |
COMPLETED | PHASE3 |
| NCT06895291 |
Whole Body MRI in Oncology |
RECRUITING | |
| NCT06866782 |
European Registry of Next Generation Imaging in Advanced Prostate Cancer |
RECRUITING | |
| NCT06769425 |
HS-10502 Combination Treatment in Patients With Advanced Solid Tumors |
RECRUITING | PHASE1 |
| NCT06555588 |
Engage Psychosocial Intervention for Cancer Symptoms |
RECRUITING | NA |
